Specialty Area
Spotlight
Topics
Institute for Value-Based Medicine
About AJMC
Podcasts
CE
Subscribe
- Center on Health Equity & Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
Optimizing Metastatic Colorectal Cancer Care: From Clinical Evidence to Real-World Excellence : Episode 9
Defining Future Needs for Real-World Evidence in mCRC
Panelists discuss how future RWE should expand to include survival, quality of life, and safety data to improve third-line mCRC care.
EP: 1.Overview of Available Third-Line Options in mCRC
EP: 2.Evidence Supporting FTD/TPI ± Bevacizumab in mCRC
EP: 3.Efficacy of Fruquintinib and Comparisons Across Agents in mCRC
EP: 4.Selecting Among Third-Line Therapies in Clinical Practice for mCRC
EP: 5.Leveraging Real-World Evidence in Sequencing Decisions for mCRC
EP: 6.Translating Real-World Outcomes in mCRC Into Patient Conversations
EP: 7.Incorporating Patient-Reported Outcomes in mCRC Into Shared Decision-Making
EP: 8.Real-World Evidence in mCRC: Special Populations and Safety Assessment
Now Viewing
EP: 9.Defining Future Needs for Real-World Evidence in mCRC
EP: 10.Applying Third-Line Therapy in mCRC: Community vs Academic Settings
EP: 11.Improving Care for mCRC: Overcoming Barriers and Building Confidence in Community Practice
EP: 12.Enhancing Support and Care Coordination in mCRC
Panelists identify gaps in current evidence and the need for more comprehensive real-world data to guide third-line therapy in metastatic colorectal cancer (mCRC).
They suggest future real-world evidence (RWE) should capture not only survival outcomes but also patient-reported quality of life, adherence, and broader safety signals.
Such data could enhance treatment personalization and support health system adoption of evidence-based third-line strategies.
Related Videos
Related Content
